Ex vivo tumor tissue platform to replace animal testing

Ministerium für Wissenschaft, Forschung und Kunst - MWK
Funding period:

01.03.2021 - 28.02.2026

Project description:

Despite massive efforts in research and development, cancer remains a major cause of death worldwide. In Germany alone, more than 200.000 mice are used as experimental animals each year for basic research as well as translational and applied research in the field of oncology. The testing of new therapies in human tumor tissue cultures represents a promising alternative for the evaluation of active substances under clinically transferable conditions. However, due to the complex biological demands and high technical requirements, robust cultivation formats for primary tumor tissues that preserve cellular heterogeneity are lacking. The establishment of a valid ex vivo technology and analytics platform based on human tumor tissues as a substitute for animal testing can only be achieved with the combined expertise of physicians, biologists and engineers, as with the 3R-US network conceived here.

Project partners

University of Stuttgart, Robert-Bosch-Krankenhaus Stuttgart

Prof. Dr. Monilola A. Olayioye
Prof. Dr. Roland Kontermann
Institute of Cell Biology and Immunology, University of Stuttgart

Jun.-Prof. Dr. Michael Heymann
Institute of Biomaterials and Biomolecular Systems, University of Stuttgart

Prof. Dr. Walter Aulitzky
Robert-Bosch-Krankenhaus Stuttgart

PD Dr. Frank Essmann
Dr. Margarete Fischer-Bosch - Institute of Clinical Pharmacology

Project coordination

Monilola Olayioye

Prof. Dr.
To the top of the page